Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive
ORGANISM(S): Homo Sapiens (human)
SUBMITTER: Minkyu Kim
LAB HEAD: Nevan Krogan
PROVIDER: PXD028733 | Pride | 2022-04-06
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
HAP1_TurboID-PARP7.zip | Other | |||
MS_Sample_Annotatons__PARP7_TurboID_.xlsx | Xlsx | |||
qx019720.raw | Raw | |||
qx019721.raw | Raw | |||
qx019722.raw | Raw |
Items per page: 1 - 5 of 9 |
Molecular cancer therapeutics 20220701 7
Inhibitors directed toward PARP1 and PARP2 are approved agents for the treatment of BRCA1 and BRCA2-related cancers. Other members of the PARP family have also been implicated in cancer and are being assessed as therapeutic targets in cancer and other diseases. Recently, an inhibitor of PARP7 (RBN-2397) has reached early-stage human clinical trials. Here, we performed a genome-wide CRISPR screen for genes that modify the response of cells to RBN-2397. We identify the polycyclic aromatic hydrocar ...[more]